Mouth Swab Molecular Test for Tuberculosis Validated
|
By LabMedica International staff writers Posted on 22 Jan 2020 |

Image: PrimeStore Molecular Transport Medium (MTM) is the first molecular transport device designed to inactivate pathogens and stabilize both RNA and DNA for downstream molecular testing and characterization (Photo courtesy of Longhorn Vaccines and Diagnostics).
Clinical investigators are testing an approach being developed to diagnose tuberculosis using mouth swabs, which could become an alternate approach to sample collection methods currently used to do tuberculosis (TB) testing.
Partly because of the convenience of the collection method, the technique is helping increase access to testing and finding people with TB that have been undetected by traditional testing methods. For individuals with latent TB infection, the host maintains a dynamic relationship with Mycobacterium tuberculosis through the regulation of available nutrients as well as the innate and acquired immune systems.
Scientists at the University of Pretoria (Pretoria, South Africa) and their colleagues collected and tested samples from people during house visits in an urban setting in South Africa with a high prevalence of TB and human immunodeficiency viruses (HIV). The team used flocked swabs to collect oral salivary specimens from 73 adults. Each person had a cough and one or more risk factors for TB, including previous TB, or was asymptomatic but residing with someone diagnosed with TB.
The investigators combined the swab samples that they had collected with PrimeStore Molecular Transport Medium (MTM, Longhorn Vaccines and Diagnostics, San Antonio, TX, USA) to enable microbial inactivation, DNA stabilization, and transportation of the specimens at ambient temperature to a nearby laboratory. The group detected M. tuberculosis DNA in 24, or 32.9%, of the 73 samples using Longhorn's polymerase chain reaction (PCR) diagnostic assay running on a Roche LightCycler platform (Roche Diagnostics, Basel, Switzerland).
P. Bernard Fourie, PhD, a professor of medical microbiology and TB specialist, said, “The approach holds promise as an easy to perform, safe, and patient-friendly procedure for triaging people who are presumed to have TB at the household level, and it provides a basis for targeted patient follow-up.”
Related Links:
University of Pretoria
Longhorn Vaccines and Diagnostics
Roche Diagnostics
Partly because of the convenience of the collection method, the technique is helping increase access to testing and finding people with TB that have been undetected by traditional testing methods. For individuals with latent TB infection, the host maintains a dynamic relationship with Mycobacterium tuberculosis through the regulation of available nutrients as well as the innate and acquired immune systems.
Scientists at the University of Pretoria (Pretoria, South Africa) and their colleagues collected and tested samples from people during house visits in an urban setting in South Africa with a high prevalence of TB and human immunodeficiency viruses (HIV). The team used flocked swabs to collect oral salivary specimens from 73 adults. Each person had a cough and one or more risk factors for TB, including previous TB, or was asymptomatic but residing with someone diagnosed with TB.
The investigators combined the swab samples that they had collected with PrimeStore Molecular Transport Medium (MTM, Longhorn Vaccines and Diagnostics, San Antonio, TX, USA) to enable microbial inactivation, DNA stabilization, and transportation of the specimens at ambient temperature to a nearby laboratory. The group detected M. tuberculosis DNA in 24, or 32.9%, of the 73 samples using Longhorn's polymerase chain reaction (PCR) diagnostic assay running on a Roche LightCycler platform (Roche Diagnostics, Basel, Switzerland).
P. Bernard Fourie, PhD, a professor of medical microbiology and TB specialist, said, “The approach holds promise as an easy to perform, safe, and patient-friendly procedure for triaging people who are presumed to have TB at the household level, and it provides a basis for targeted patient follow-up.”
Related Links:
University of Pretoria
Longhorn Vaccines and Diagnostics
Roche Diagnostics
Latest Microbiology News
- Gut Microbiome Signatures Help Identify Risk of IBD Progression
- FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
- New AMR Assay Supports Rapid Infection Control Screening in Hospitals
- Diagnostic Gaps Complicate Bundibugyo Ebola Outbreak Response in Congo
- Study Finds Hidden Mpox Infections May Drive Ongoing Spread
- Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals
- Molecular Urine and Stool Tests Do Not Improve Early TB Treatment in Hospitalized HIV Patients
- Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
- Label-Free Microscopy Method Enables Faster, Quantitative Detection of Malaria
- Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
- Gut Microbiome Test Predicts Melanoma Recurrence After Surgery
- Rapid Blood-Culture Susceptibility Panel Expands Coverage for Gram-Negative Infections
- Antibiotic Resistance Genes Found in Newborns Within Hours of Birth
- Rapid Color Test Stratifies Virulent and Resistant Staph Strains
- mNGS CSF Test Identifies CNS Pathogens Missed by Standard Panels
- Syndromic Panel Enables Rapid Identification of Bloodstream Infections
Channels
Clinical Chemistry
view channel
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read more
Urine-Based Test Shows Promise for Autism Screening in Children
Autism spectrum disorder (ASD) is commonly diagnosed through behavioral assessments, which can involve long waits that delay intervention. Earlier identification is linked to better developmental outcomes,... Read moreMolecular Diagnostics
view channel
Blood-Based Assay Enables Noninvasive Monitoring of Sarcoma Immunotherapy Response
Sarcomas remain difficult to monitor during immunotherapy, as low tumor mutation burden can limit traditional circulating tumor DNA approaches and repeat tissue biopsies are often impractical in advanced disease.... Read more
Tumor Mutation Marker Helps Refine Lung Cancer Prognosis and Guide Therapy Selection
Lung cancer remains the leading cause of cancer death worldwide, while heterogeneous tumor genetics continue to complicate treatment decisions. Although molecular testing is increasingly used to match... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read morePathology
view channel
AI-Powered Atlas Maps Immune Structures Linked to Cancer Outcomes
Tertiary lymphoid structures are emerging as important indicators of antitumor immunity, but their heterogeneity and spatial context within tumors remain difficult to capture through routine diagnostics.... Read more
AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy
Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel








